APA (7th ed.) Citation

Kähler, K. C., Gutzmer, R., Meier, F., Zimmer, L., Heppt, M., Gesierich, A., . . . Ugurel, S. (2021). Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. Frontiers in oncology, 11, 672172. https://doi.org/10.3389/fonc.2021.672172

Chicago Style (17th ed.) Citation

Kähler, Katharina C., et al. "Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study." Frontiers in Oncology 11 (2021): 672172. https://doi.org/10.3389/fonc.2021.672172.

MLA (9th ed.) Citation

Kähler, Katharina C., et al. "Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study." Frontiers in Oncology, vol. 11, 2021, p. 672172, https://doi.org/10.3389/fonc.2021.672172.